Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Nektar Therapeutics (NASDAQ:NKTR) reported inducement grants made on May 20, 2026 under its 2025 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The Board’s committee granted non-qualified options for 11,900 shares to five new employees at a $69.49 exercise price, with eight-year terms and four-year vesting.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
NKTR fell 8.3% with elevated volume, while close peers showed mixed moves (e.g., SANA up 2.86%, PRAX down 15.94%), pointing to stock-specific pressure rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 27 | Conference participation | Neutral | -0.6% | Announcement of participation in Jefferies Global Healthcare Conference and webcast access. |
| May 07 | Quarterly earnings | Negative | -1.8% | Q1 2026 results with $10.9M revenue and $44.9M net loss reported. |
| May 01 | Inducement grants | Neutral | +0.5% | Inducement equity grants of 28,450 options and 2,950 RSUs to new hires. |
| Apr 28 | Earnings date set | Neutral | -0.7% | Scheduling of Q1 2026 earnings release and related conference call details. |
| Apr 23 | Equity offering | Negative | +0.5% | Closing of $373.8M public offering of 4,062,500 shares at $92.00 per share. |
Recent news—including earnings, offerings, and prior inducement grants—has generally seen modest price reactions, with only one clear divergence from expected sentiment.
Over recent months, Nektar has combined financing activity with steady corporate updates. An April offering raised $373.8 million, followed by an earnings release highlighting a $44.9 million net loss on $10.9 million revenue and a strengthened cash balance. The company has also issued multiple inducement equity awards under its 2025 Inducement Plan and participated in investor conferences. Historically, these updates have produced relatively small share moves, providing context for interpreting today’s HR-related inducement grants.
Market Pulse Summary
This announcement details modest inducement option grants of 11,900 shares to new employees at an exercise price of $69.49, matching the May 20, 2026 close. The eight-year term and four-year vesting mirror standard equity compensation under Nektar’s 2025 Inducement Plan. In context of recent financings, earnings results, and prior inducement grants, this news mainly signals ongoing hiring and retention efforts rather than a change in strategic or financial trajectory.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
non-qualified stock options financial
exercise price financial
AI-generated analysis. Not financial advice.
Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price per share equal to
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements which can be identified by words such as: "could," "develop," "evaluate," "address," "may" and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the therapeutic potential of, and future development plans for, rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are in clinical or preclinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) data reported from ongoing clinical trials are necessarily interim data only and the final results will change based on continuing observations; (v) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (vi) a Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States; (vii) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (viii) certain other important risks and uncertainties set forth in our Annual Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2026. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contacts:
For Investors:
Vivian Wu
VWu@nektar.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577
For Media:
Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302790582.html
SOURCE Nektar Therapeutics